8 Analysts Have This To Say About Integra Lifesciences
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have published ratings on Integra Lifesciences (NASDAQ:IART), showing a range of perspectives from bullish to bearish. The average 12-month price target is $28.12, with a high of $40.00 and a low of $24.00. Recent analyst actions include both raises and lowers in ratings and price targets.
July 15, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed views on Integra Lifesciences, with recent ratings showing a range from somewhat bullish to somewhat bearish. The average price target has declined by 21.34% to $28.12. Recent actions include both raises and lowers in ratings and price targets.
The mixed analyst ratings and the significant decline in the average price target suggest uncertainty about Integra Lifesciences' short-term performance. The range of recent actions, including both raises and lowers in ratings and price targets, indicates a lack of consensus among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100